| |
eNOS
|
P value (< 0.05)
|
|---|
|
GG %
|
GT %
|
TT %
| |
|---|
|
Age
|
58.6 ± 9.34
|
61.77 ± 10.1
|
60.87 ± 10.25
|
0.07
|
|
Gender
| | | |
0.4
|
|
♀
|
2.6
|
39.7
|
57.7
| |
|
♂
|
6.9
|
34.5
|
58.6
| |
|
Ethnicity
| | | |
0.5
|
|
White
|
4.5
|
41
|
54.5
| |
|
Metis
|
3.4
|
34.8
|
61.8
| |
|
Black
|
0
|
58.3
|
41.7
| |
|
Familial History of EH
| | | |
0.5
|
|
yes
|
4.5
|
39.8
|
55.7
| |
|
no
|
1.8
|
36.8
|
61.4
| |
|
Familial History of CVD
| | | |
0.6
|
|
yes
|
5.9
|
38.2
|
55.9
| |
|
no
|
2.7
|
38.7
|
58.6
| |
|
Familial History of Cerebrovascular disease
| | | |
0.9
|
|
yes
|
2.6
|
36.9
|
60.5
| |
|
no
|
3.7
|
39.3
|
57
| |
|
Familial History of Diabetes
| | | |
0.3
|
|
yes
|
3.8
|
43.6
|
52.6
| |
|
no
|
3
|
32.8
|
64.2
| |
|
Familial History of Renal disease
| | | |
0.8
|
|
yes
|
0
|
40
|
60
| |
|
no
|
3.7
|
38.5
|
57.8
| |
|
Familial History of Dyslipidemia
| | | |
0.3
|
|
yes
|
4.7
|
30.2
|
65.1
| |
|
no
|
2.9
|
42.2
|
54.9
| |
|
Smoking
| | | |
0.2
|
|
yes
|
7.7
|
53.8
|
38.5
| |
|
no
|
3
|
37.1
|
59.9
| |
|
Alcohol
| | | |
0.009*
|
|
yes
|
25
|
75
|
0
| |
|
no
|
2.8
|
37.6
|
59.6
| |
|
Physical Activity
| | | |
0.05
|
|
yes
|
7.1
|
35.7
|
57.1
| |
|
no
|
0
|
41.3
|
58.7
| |
|
Obesity
| | | |
0.02*
|
|
yes
|
6.5
|
27.4
|
66.1
| |
|
no
|
1.2
|
47
|
51.8
| |
|
Dyslipidemia
| | | |
0.9
|
|
yes
|
3.4
|
37.9
|
58.6
| |
|
no
|
3.4
|
39.1
|
57.5
| |
|
Diabetes
| | | |
0.9
|
|
yes
|
3.8
|
37.7
|
58.5
| |
|
no
|
3.3
|
39.1
|
57.6
| |
|
Menopausal status
| | | |
0.2
|
|
yes
|
3
|
32.8
|
64.2
| |
|
no
|
2
|
48
|
50
| |
|
Personal History of CVD
| | | |
0.07
|
|
yes
|
9.7
|
29
|
61.3
| |
|
no
|
1.9
|
42.9
|
55.2
| |
|
Nephropathy
| | | |
0.8
|
|
yes
|
0
|
33.3
|
66.7
| |
|
no
|
3.6
|
38.8
|
57.6
| |
|
Nbr of antihypertensive molecules
| | | |
0.7
|
|
1
|
3.1
|
37.5
|
59.4
| |
|
2
|
5.1
|
42.3
|
52.6
| |
|
3
|
0
|
36
|
64
| |
|
4
|
0
|
22.2
|
77.8
| |
|
TA
| | | |
0.7
|
|
controled
|
4.3
|
37.2
|
58.5
| |
|
non-controled
|
2
|
41.2
|
56.8
| |
|
Neurological deficit
| | | |
0.7
|
|
yes
|
0
|
33.3
|
66.7
| |
|
no
|
3.7
|
39
|
57.3
| |
|
Electrical HVG
| | | |
0.7
|
|
yes
|
0
|
38.5
|
61.5
| |
|
no
|
3.8
|
38.6
|
57.6
| |
|
Repolarisation troubles
| | | |
0.5
|
|
yes
|
5.8
|
47.1
|
47.1
| |
|
no
|
3.1
|
37.5
|
59.4
| |
|
Creatinine
|
7.9 ± 4.14
|
11.38 ± 6.21
| |
0.2
|
|
TG
| | | |
0.5
|
|
≤ 1
|
4.5
|
41
|
54.5
| |
|
> 1
|
2.4
|
31.3
|
66.3
| |
|
CT
| | | |
0.3
|
|
≤ 1
|
0
|
0
|
3
| |
|
> 1
|
2.8
|
36.7
|
60.6
| |
|
HDL
| | | |
0.8
|
|
≤ 0.5
|
2
|
36
|
62.8
| |
|
> 0.5
|
3.8
|
32.1
|
64.2
| |
|
LDL
| | | |
0.9
|
|
≤ 0.5
|
0
|
0
|
100
| |
|
> 0.5
|
3
|
31
|
66
| |
|
Glucose
|
1.02 ± 0.48
|
1.18 ± 0.56
|
1.32 ± 0.6
|
0.9
|
|
Na+
|
137 ± 28
|
139.6 ± 34.9
|
135.3 ± 20.6
|
0.3
|
|
K+
|
4.1 ± 1.8
|
4.06 ± 1.9
|
4.22 ± 1.8
|
0.3
|
- *Statistically significant; Nbr number, HVG left ventricular hypertrophy, GG Homozygous wild type, GT Heterozygous, TT Homozygous mutant
